PharmaBoardroom

Gilead’s Remdesivir: No Overnight Success Story

With remdesivir practically a household name today as the first therapeutic to be approved for the treatment of COVID-19 patients, Gilead chairman and…

Jon Amund Kyte – Head, Department of Experimental Cancer…

[caption id="attachment_92156" align="alignleft" width="227"] Photo: Sofia Linden / Oslo Cancer Cluster[/caption] Oncologist Jon Amund Kyte shares…

Martin Naville – CEO, Swiss-American Chamber of Commerce

In a wide-ranging conversation, Martin Naville of AmCham Switzerland looks at the evolution of the Switzerland-US trade relationship and the…

Anette Margrethe Storstein – Chair of the Board, Norwegian…

Anette Margrethe Storstein MD PhD of the Norwegian Brain Council introduces the burden of neurodegenerative disease in Norway today, the ongoing…

Norway: Staking a Claim as a Pharma Research Hub

Norway, more well-known internationally as an innovation hub for oil & gas and marine biology, is attempting to reverse the trend of reducing…

Indian Pharma Market to Grow by 12-14% Up to 2023

The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14…

Chinese Biotech Strategies: Biologics or Small Molecules

While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception…

Pharma’s Data Problem

Drs David Higgins and Marco F Schmidt highlight the gap that exists between the abundant discussions around technological innovation in healthcare and…

Aducanumab: On the Regulatory Home Stretch in the USA

In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…

Ole Alexander Opdalshei – Assistant Secretary General,…

Ole Alexander Opdalshei introduces the role of the Norwegian Cancer Society within Norwegian cancer research, care services and information…

Chinese Biotech Strategies: The Pros & Cons of In-Licensing

Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios…

Switzerland Innovation & Competitiveness Snapshot 2020

In just a few years, Switzerland has fallen from first to fifth place in the Global Competitiveness Index. The country is also losing ground in…

Tagged with